Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment

被引:0
|
作者
Li, Shaobo [1 ,2 ]
Zhang, Min [3 ]
Liu, Jin [4 ]
Liu, Shaojun [3 ]
Zhu, Chen [1 ]
Shang, Da [3 ]
Guan, Yi [3 ]
Wang, Qian [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China
[2] Inner Mongolia Med Univ, Peking Univ Canc Hosp, Dept Nucl Med, Affiliated Canc Hosp, Inner Mongolia Campus, Hohhot 010020, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Nephrol, Shanghai 200040, Peoples R China
[4] Naval Med Univ, Changzheng Hosp, Dept Hematol Myeloma & Lymphoma Ctr, Shanghai 200003, Peoples R China
关键词
Multiple myeloma; Myeloma nephropathy; Renal impairment recovery; Risk nomogram; BORTEZOMIB-BASED CHEMOTHERAPY; CAST NEPHROPATHY; STAGING SYSTEM; HIGH-CUTOFF; FAILURE; HEMODIALYSIS; DISEASE; SAFETY; INDEPENDENCE; MULTICENTER;
D O I
10.1016/j.currproblcancer.2023.100962
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine risk factors affecting renal recovery in newly diagnosed multiple myeloma (NDMM) patients with renal impairment (RI) and establish a risk nomogram. This multi-center, retrospective cohort study included 187 NDMM patients with RI, 127 of whom were admitted to Huashan Hospital and assigned to the training cohort and 60 were admitted to Changzheng Hospital and assigned to the external validation cohort. The baseline data of the 2 cohorts were compared, and survival and renal recovery rates were analyzed. Independent risk factors affecting renal recovery were determined by binary logistic regression analysis, and a risk nomogram was established and subsequently tested in the external validation cohort. Results: The median overall survival (OS) improved in patients who achieved renal recovery etc within 6 courses of MM directed treatment compared with patients without renal recovery. Median time to renal recovery was 2.65 courses, and the cumulative renal recovery rate during the first 3 courses was 75.05%. Involved serum free light chain (sFLC) ratio of > 120 at diagnosis, time from renal impairment to treatment > 60 days, and a hematologic response without a very good partial remission (VGPR) or better resulted as independent risk factors for renal recovery during the first 3 courses. The established risk nomogram had good discriminative ability and accuracy. Involved sFLC was a key factor affecting renal recovery. Starting treatment as soon as possible after detecting RI and achieving deep hematologic remission during the first 3 courses of treatment helped achieve renal recovery and improve prognosis.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Bortezomib and Dexamethasone Therapy for Newly Diagnosed Patients With Multiple Myeloma Complicated by Renal Impairment
    Li, Jian
    Zhou, Dao-Bin
    Jiao, Li
    Duan, Ming Hui
    Zhang, Wei
    Zhao, Yong Qiang
    Shen, Ti
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (05): : 394 - 398
  • [12] Renal recovery is a favorable prognostic marker in patients with newly-diagnosed multiple myeloma
    Badea, M.
    Badea, D.
    Genuche, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 202 - 203
  • [13] Management of multiple myeloma-related renal impairment: recommendations from the International MyelomaWorking Group
    Dimopoulos, Meletios A.
    Merlini, Giampaolo
    Bridoux, Frank
    Leung, Nelson
    Mikhael, Joseph
    Harrison, Simon J.
    Kastritis, Efstathios
    Garderet, Laurent
    Gozzetti, Alessandro
    van de Donk, Niels W. C. J.
    Weisel, Katja C.
    Badros, Ashraf Z.
    Beksac, Meral
    Hillengass, Jens
    Mohty, Mohamad
    Ho, P. Joy
    Ntanasis-Stathopoulos, Ioannis
    Mateos, Maria-Victoria
    Richardson, Paul
    Blade, Joan
    Moreau, Philippe
    San-Miguel, Jesus
    Munshi, Nikhil
    Rajkumar, S. Vincent
    Durie, Brian G. M.
    Ludwig, Heinz
    Terpos, Evangelos
    LANCET ONCOLOGY, 2023, 24 (07): : E293 - E311
  • [14] The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
    M A Dimopoulos
    M Roussou
    M Gkotzamanidou
    N Nikitas
    E Psimenou
    D Mparmparoussi
    C Matsouka
    M Spyropoulou-Vlachou
    E Terpos
    E Kastritis
    Leukemia, 2013, 27 : 423 - 429
  • [15] The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
    Dimopoulos, M. A.
    Roussou, M.
    Gkotzamanidou, M.
    Nikitas, N.
    Psimenou, E.
    Mparmparoussi, D.
    Matsouka, C.
    Spyropoulou-Vlachou, M.
    Terpos, E.
    Kastritis, E.
    LEUKEMIA, 2013, 27 (02) : 423 - 429
  • [16] Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients
    Chen, Xuduan
    Luo, Xiaofeng
    Zu, Yanping
    Issa, Hajji Ally
    Li, Linlin
    Ye, Hong
    Yang, Ting
    Hu, Jianda
    Wei, Lixin
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2020, 34 (09)
  • [17] IMPACT OF RENAL IMPAIRMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA IN A REAL WORLD SETTING
    Bove, V.
    Villano, F.
    Diaz, L.
    Riva, E.
    HAEMATOLOGICA, 2017, 102 : 776 - 776
  • [18] Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma
    Derman, Benjamin A.
    Reiser, Jochen
    Basu, Sanjib
    Paner, Agne
    INTERNATIONAL JOURNAL OF NEPHROLOGY, 2018, 2018
  • [19] International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
    Dimopoulos, Meletios A.
    Sonneveld, Pieter
    Leung, Nelson
    Merlini, Giampaolo
    Ludwig, Heinz
    Kastritis, Efstathios
    Goldschmidt, Hartmut
    Joshua, Douglas
    Orlowski, Robert Z.
    Powles, Raymond
    Vesole, David H.
    Garderet, Laurent
    Einsele, Hermann
    Palumbo, Antonio
    Cavo, Michele
    Richardson, Paul G.
    Moreau, Philippe
    San Miguel, Jesus
    Rajkumar, S. Vincent
    Durie, Brian G. M.
    Terpos, Evangelos
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (13) : 1544 - +
  • [20] Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment
    Guangzhong Yang
    Wenming Chen
    Yin Wu
    Chinese Journal of Cancer Research, 2013, 25 (02) : 155 - 160